Skip to main content
Top

Clinical & Experimental Metastasis

Issue 3/2004

Content (12 Articles)

ICAM-1 supports adhesion of human small-cell lung carcinoma to endothelial cells

Angela H. Finzel, Armin J. Reininger, Patrick A. Bode, Laurenz J. Wurzinger

Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: Inhibition by gefitinib (`Iressa', ZD1839)

Stephen Hiscox, Liam Morgan, Denise Barrow, Carol Dutkowski, Alan Wakeling, Robert I. Nicholson

The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions

Ben Davidson, Iris Goldberg, Liora Tell, Sophya Vigdorchik, Mark Baekelandt, Aasmund Berner, Gunnar B. Kristensen, Reuven Reich, Juri Kopolovic

Differences between scirrhous and non-scirrhous human gastric carcinomas from the aspect of proMMP-2 activation regulated by TIMP-3

Takeyoshi Yokoyama, Hiroyuki Nakamura, Yoshihide Otani, Tetsuro Kubota, Noboru Fujimoto, Motoharu Seiki, Masaki Kitajima, Yasunori Okada

Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice

Makiya Nishikawa, Ayumi Tamada, Kenji Hyoudou, Yukari Umeyama, Yuki Takahashi, Yuki Kobayashi, Hitomi Kumai, Emi Ishida, Frantisek Staud, Yoshiyuki Yabe, Yoshinobu Takakura, Fumiyoshi Yamashita, Mitsuru Hashida

Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma

Masanao Saio, Matt Teicher, Gaynor Campbell, Helen Feiner, Yara Delgado, Alan B. Frey

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine